Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Expands By 26.9%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 2,304,530 shares, an increase of 26.9% from the March 15th total of 1,816,131 shares. Currently, 5.6% of the shares of the stock are short sold. Based on an average trading volume of 801,291 shares, the days-to-cover ratio is currently 2.9 days.

MAIA Biotechnology Trading Up 1.5%

MAIA stock opened at $1.35 on Friday. The firm has a 50-day moving average price of $1.62 and a 200-day moving average price of $1.54. MAIA Biotechnology has a 12 month low of $0.87 and a 12 month high of $3.19. The stock has a market capitalization of $81.90 million, a P/E ratio of -1.96 and a beta of 0.30.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. As a group, equities analysts predict that MAIA Biotechnology will post -1.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares during the last quarter. Marshall Wace LLP bought a new stake in MAIA Biotechnology during the 2nd quarter worth $29,000. Jane Street Group LLC bought a new stake in MAIA Biotechnology during the 2nd quarter worth $52,000. Ritholtz Wealth Management acquired a new position in MAIA Biotechnology in the 4th quarter worth about $35,000. Finally, Centric Wealth Management increased its holdings in MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after purchasing an additional 11,500 shares in the last quarter. 5.65% of the stock is currently owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.